ALYREF and prostate cancer: In prostate cancer, ACC1 mRNA in the m5C modified state interacts with ALYREF to enhance its stability and facilitate nuclear export, resulting in lipid accumulation and progression of prostate cancer (Zhang et al., 2023b).